FN Thomson Reuters Web of Knowledge VR 1.0 PT J AU Sabatier, V Rousselle, T Mangematin, V AF Sabatier, Valerie Rousselle, Tristan Mangematin, Vincent TI Building your portfolio of business models SO BIOFUTUR LA French DT Article C1 [Sabatier, V] Grenoble Appl Econ Lab, Grenoble, France. [Sabatier, V; Mangematin, V] Grenoble Ecole Management, Grenoble, France. RP Sabatier, V (reprint author), Grenoble Appl Econ Lab, Grenoble, France EM vincent.mangematin@grenoble-em.com CR Teece DJ, 2010, LONG RANGE PLANN, V43, P172 SABATIER V, 2010, LONG RANGE PLANNING, V43 Sabatier V, 2010, PROD PLAN CONTROL, V21, P218 Pisano GP, 2006, HARVARD BUS REV, V84, P114 NR 4 TC 0 Z9 0 PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER PI PARIS PA 23 RUE LINOIS, 75724 PARIS, FRANCE SN 0294-3506 J9 BIOFUTUR JI Biofutur PD MAR PY 2011 IS 319 BP 56 EP 59 PG 4 WC Biotechnology & Applied Microbiology SC Biotechnology & Applied Microbiology GA 745RK UT WOS:000289183200010 ER PT J AU Lalandes, R Thomas, AL El Fajoui, Z Jani, SAM Ganesan, B Le, P Mangematin, V Amir-Aslani, A AF Lalandes, Romain Thomas, Anne-Laure El Fajoui, Zineb Jani, Siavash Ali Madadi Ganesan, Balaji Le, Philippe Mangematin, Vincent Amir-Aslani, Arsia TI The biotech bend in the pharmaceutical industry SO BIOFUTUR LA French DT Article C1 [Lalandes, R; Thomas, AL; El Fajoui, Z; Jani, SAM; Ganesan, B; Le, P; Mangematin, V; Amir-Aslani, A] Grenoble Ecole Management, Grenoble, France. RP Lalandes, R (reprint author), Grenoble Ecole Management, Grenoble, France EM arsia.amir-aslani@grenoble-em.com CR DiMasi JA, 2010, CLIN PHARMACOL THER, V87, P272 NR 1 TC 0 Z9 0 PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER PI PARIS PA 23 RUE LINOIS, 75724 PARIS, FRANCE SN 0294-3506 J9 BIOFUTUR JI Biofutur PD JAN PY 2011 IS 317 BP 52 EP 53 PG 2 WC Biotechnology & Applied Microbiology SC Biotechnology & Applied Microbiology GA 727XD UT WOS:000287835600011 ER PT J AU Sabatier, V Mangematin, V Rousselle, T AF Sabatier, Valerie Mangematin, Vincent Rousselle, Tristan TI From Recipe to Dinner: Business Model Portfolios in the European Biopharmaceutical Industry SO LONG RANGE PLANNING LA English DT Article ID BIOTECHNOLOGY FIRMS; INNOVATION AB This article builds on the analogy between the business model concept and a recipe to discuss the concept of a business model portfolio (which we analogise as a dinner). In this context, we view analogies as concise, shorthand ways to describe important concepts and propose principles to organise new ways to make money in existing activities. Considering the different business models of four European biotechnology companies, we explore the their business model portfolios, defined as the range of different ways they deliver value to their customers to ensure both their medium term viability and future development. A firm's portfolio can help balance the levels of promise and interdependency with other firms of its different business models, and help it articulate and finance its activities in the medium run to ensure idiosyncrasy to protect its future health. (C) 2010 Elsevier Ltd. All rights reserved. C1 [Sabatier, V] Grenoble Ecole Management, GAEL UMR INRA UPMF, F-38000 Grenoble, France. [Rousselle, T] PX Therapeut, MINATEC BHT 52 B, F-38040 Grenoble 9, France. RP Sabatier, V (reprint author), Grenoble Ecole Management, GAEL UMR INRA UPMF, 12 Rue Pierre Semard, F-38000 Grenoble, France EM valerie.sabatier@grenoble-em.com vincent.mangematin@grenoble-em.com tristanrousselle@px-therapeutics.com CR Baden-Fuller C, 2010, LONG RANGE PLANN, V43, P156 Gambardella A, 2010, LONG RANGE PLANN, V43, P262 Teece DJ, 2010, LONG RANGE PLANN, V43, P172 Zott C, 2010, LONG RANGE PLANN, V43, P216 ZHANG JJ, 2008, BROKERAGE FIRM NETWO Casper S, 2007, RES POLICY, V36, P438, DOI 10.1016/j.respol.2007.02.018 Hopkins MM, 2007, RES POLICY, V36, P566, DOI 10.1016/j.respol.2007.02.013 Mc Namara P, 2007, RES POLICY, V36, P548, DOI 10.1016/j.respol.2007.02.012 HUNTER L, 2006, EUROPEAN MANAGEMENT, V24, P315, DOI 10.1016/j.emj.2006.08.001 ROTHMAN H, 2006, J COMMERCIAL BIOTECH, V12, P86, DOI 10.1057/palgrave.jcb.3040154 Morris M, 2005, J BUS RES, V58, P726, DOI 10.1016/j.jbusres.2003.11.001 SCHWEIZER L, 2005, J GEN MANAGE, V31, P37 VOELPEL SC, 2004, J CHANGE MANAGEMENT, V4, P259, DOI 10.1080/1469701042000212669 Gittelman M, 2003, MANAGE SCI, V49, P366, DOI 10.1287/mnsc.49.4.366.14420 Mangematin V, 2003, RES POLICY, V32, P621, DOI 10.1016/S0048-7333(02)00045-8 DiMasi JA, 2003, J HEALTH ECON, V22, P151, DOI 10.1016/S0167-6296(02)00126-1 Chesbrough H, 2002, IND CORP CHANGE, V11, P529, DOI 10.1093/icc/11.3.529 Magretta J, 2002, HARVARD BUS REV, V80, P86 Mowery DC, 2001, RES POLICY, V30, P99, DOI 10.1016/S0048-7333(99)00100-6 AFUAH A, 1997, IND CORP CHANGE, V6, P183 PETTIGREW AM, 1990, ORG SCI, V1 NR 21 TC 4 Z9 4 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0024-6301 J9 LONG RANGE PLANN JI Long Range Plan. PD APR-JUN PY 2010 VL 43 IS 2-3 SI SI BP 431 EP 447 DI 10.1016/j.lrp.2010.02.001 PG 17 WC Business; Management; Planning & Development SC Business & Economics; Public Administration GA 605NU UT WOS:000278355100019 ER PT J AU Amir-Aslani, A Mangematin, V AF Amir-Aslani, Arsia Mangematin, Vincent TI The future of drug discovery and development: Shifting emphasis towards personalized medicine SO TECHNOLOGICAL FORECASTING AND SOCIAL CHANGE LA English DT Article DE Biomarkers; Diagnostics; Theranostics; Innovation; Personalized medicine ID BIOMARKERS; PHARMACOGENETICS; SITAGLIPTIN; INHIBITOR; REALITY; CANCER; STILL; FOCUS AB The drug discovery sector is being revolutionized by the current rate of advances in the public and private human genome projects and by the development of new technologies for biomarker testing. in effect, as the genetic roots of disease, disease progression and treatment effectiveness are uncovered, the demand for sophisticated prognostic. diagnostic and monitoring tests will be increasing. Already this has led to the development of innovative diagnostics products meeting the criteria of improved efficacy and safety as well as better cost-benefits. In order to achieve the ultimate goal of a more predictive and personalized medicine requires the drug discovery industry to implement more synergies between the two worlds of clinical research and diagnostics. The therapeutics that are enabled by that strategy are often called "theranostics" - highly specific tests that allow for the diagnosis of the disease, but to administer the most appropriate treatment regimen, and to monitor a patient's response to therapy. Biomarkers will constitute a critical component of the health care delivery system in order to detect, diagnose and monitor diseases and other medical conditions as well as to evaluate treatment options and effectiveness. While diagnostic breakthroughs typically precede therapeutic advances, the presence of new therapies can stimulate the demand for testing. The main question that remains to be answered is how will the biomarker paradigm alters these companies' innovation and commercialization strategies. Whereas developing drug targets may offer greater long-term value, initial commercial opportunities often arise in diagnostics. (C) 2009 Published by Elsevier Inc. C1 [Amir-Aslani, A; Mangematin, V] Grenoble Ecole Management, F-38003 Grenoble 01, France. RP Amir-Aslani, A (reprint author), Grenoble Ecole Management, 12 Rue Pierre Semard, F-38003 Grenoble 01, France EM a.amir-aslani@araxes-associates.com CR Melander O, 2009, JAMA-J AM MED ASSOC, V302, P49 Stevens JL, 2009, DRUG DISCOV TODAY, V14, P162 AMIRASLANI A, 2009, J TECHNOL MANAG INNO, V4, P54 HEATH JR, 2009, SCI AM FEB, P44 Manolio TA, 2009, ANNU REV MED, V60, P443, DOI 10.1146/annurev.med.60.061907.093117 Ryan TP, 2008, CURR OPIN PHARMACOL, V8, P654, DOI 10.1016/j.coph.2008.07.011 Czerepak EA, 2008, NAT REV DRUG DISCOV, V7, P197, DOI 10.1038/nrd2531 AMIRASLANI A, 2008, TECHNOL FORECAST SOC, V7, P905 CARLQUIST JF, 2008, THERAPY, V5, P125, DOI 10.2217/14750708.5.2.125 HUANG SM, 2008, INFORMA Wagner JA, 2008, ANNU REV PHARMACOL, V48, P631, DOI 10.1146/annurev.pharmtox.48.113006.094611 Anderson JL, 2007, CIRCULATION, V116, P2563, DOI 10.1161/CIRCULATIONAHA.107.737312 Marchetti S, 2007, BRIT J CANCER, V97, P577, DOI 10.1038/sj.bjc.6603925 Nevins JR, 2007, NAT REV GENET, V8, P601, DOI 10.1038/nrg2137 Herman GA, 2007, CLIN PHARMACOL THER, V81, P761, DOI 10.1038/sj.clpt.6100167 Cressey TR, 2007, INFECT GENET EVOL, V7, P333, DOI 10.1016/j.meegid.2006.08.004 CHO WCS, 2007, GENOM PROTEOM BIOINF, V5, P77, DOI 10.1016/S1672-0229(07)60018-7 MARSUINA K, 2007, GENETIC ENG BIOTECHN, P2007 SCOTT R, 2007, INT J CLIN PRACT, V61, P1 Bepler G, 2006, LUNG CANCER, V54, pS3, DOI 10.1016/j.lungcan.2006.09.014 Longley DB, 2006, BBA-REV CANCER, V1766, P184, DOI 10.1016/j.bbcan.2006.08.001 Herman GA, 2006, J CLIN ENDOCR METAB, V91, P4612, DOI 10.1210/jc.2006-1009 Hopkins MM, 2006, NAT BIOTECHNOL, V24, P403, DOI 10.1038/nbt0406-403 Twombly R, 2006, J NATL CANCER I, V98, P11 KAITIN KI, 2006, DEV CONSISTENTLY BES, V8 Kim D, 2005, J MED CHEM, V48, P141, DOI 10.1021/jm0493156 Claudio JO, 2005, AM J PHARMACOGENOMIC, V5, P35, DOI 10.2165/00129785-200505010-00003 OBEREMM A, 2005, TOXICOL APPL PHARM, V207, pS592 SHAFER SM, 2005, BUS HORIZONS, V48, P199, DOI 10.1016/j.bushor.2004.10.014 Nassar AEF, 2004, DRUG DISCOV TODAY, V9, P1055, DOI 10.1016/S1359-6446(04)03297-0 Dickson M, 2004, NAT REV DRUG DISCOV, V3, P417, DOI 10.1038/nrd1382 Cohen MH, 2004, CLIN CANCER RES, V10, P1212, DOI 10.1158/1078-0432.CCR-03-0564 BAIN W, 2004, DRUG DISCOV WORL FAL, P9 *FDA, 2004, INN STAGN CHALL OPP McLean LA, 2004, CLIN CANCER RES, V10, P155, DOI 10.1158/1078-0432.CCR-0784-3 Kubinyi H, 2003, NAT REV DRUG DISCOV, V2, P665, DOI 10.1038/nrd1156 Noble D, 2003, TRENDS BIOTECHNOL, V21, P333, DOI 10.1016/S0167-7799(03)00162-8 DiMasi JA, 2003, J HEALTH ECON, V22, P151, DOI 10.1016/S0167-6296(02)00126-1 Fogarty M, 2002, SCIENTIST, V16, P35 Lasser KE, 2002, JAMA-J AM MED ASSOC, V287, P2215, DOI 10.1001/jama.287.17.2215 Horrobin DE, 2001, NAT BIOTECHNOL, V19, P1099, DOI 10.1038/nbt1201-1099 Shillingford CA, 2001, DRUG DISCOV TODAY, V6, P941, DOI 10.1016/S1359-6446(01)01945-6 Baba Y, 2001, EUR J PHARM SCI, V13, P3, DOI 10.1016/S0928-0987(00)00201-3 Li AP, 2001, DRUG DISCOV TODAY, V6, P357, DOI 10.1016/S1359-6446(01)01712-3 Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200 NR 45 TC 2 Z9 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0040-1625 J9 TECHNOL FORECAST SOC JI Technol. Forecast. Soc. Chang. PD FEB PY 2010 VL 77 IS 2 BP 203 EP 217 DI 10.1016/j.techfore.2009.09.005 PG 15 WC Business; Planning & Development SC Business & Economics; Public Administration GA 555ZO UT WOS:000274555900003 ER PT J AU Sabatier, V Mangematin, V Rousselle, T AF Sabatier, V. Mangematin, V. Rousselle, T. TI Orchestrating networks in the biopharmaceutical industry: small hub firms can do it SO PRODUCTION PLANNING & CONTROL LA English DT Article DE hub firm; network; business model; biotechnology; value chain ID RESEARCH-AND-DEVELOPMENT; INTERFIRM COOPERATION; SCIENTIFIC KNOWLEDGE; BIOTECHNOLOGY; INNOVATION; COLLABORATION; PERFORMANCE; ORGANIZATION; TECHNOLOGY; EXPERIENCE AB The biopharmaceutical industry has been one of the most dynamic and promising sectors. The entry of Biotechnology start-ups in the 1980s led to the reconfiguration of the drug development value chain and the emergence of new competences. As the sector evolved, specialised firms appeared. As the industry matures, the production process becomes more specialised to support optimisation of technological steps. Our case studies reveal that the coordination of networks can be specialised, with the emergence of Dedicated Coordinating Firms. On the basis of four case studies of European biotechnology companies within a business model approach, this article helps understanding how coordinating a network can be successful and how small hub firms can do it. C1 [Sabatier, V] Univ Grenoble 2, GAEL, UMR 1215, F-38000 Grenoble, France. [Sabatier, V; Mangematin, V] Grenoble Ecole Management, F-38000 Grenoble, France. [Sabatier, V; Rousselle, T] PXTherapeutics, F-38000 Grenoble, France. RP Sabatier, V (reprint author), Univ Grenoble 2, GAEL, UMR 1215, F-38000 Grenoble, France EM valerie.sabatier@grenoble-em.com CR Durand R, 2008, STRATEG MANAGE J, V29, P1281, DOI 10.1002/smj.707 Howells J, 2008, R&D MANAGE, V38, P205, DOI 10.1111/j.1467-9310.2008.00508.x PAPANIA L, 2008, J COMMERCIAL BIOTECH, V14, P247, DOI 10.1057/jcb.2008.14 SABATIER V, 2008, 9 WORK C VIRT ENT PO Hopkins MM, 2007, RES POLICY, V36, P566, DOI 10.1016/j.respol.2007.02.013 Zhang J, 2007, RES POLICY, V36, P515, DOI 10.1016/j.respol.2007.02.015 Siggelkow N, 2007, ACAD MANAGE J, V50, P20 Chesbrough H, 2007, RES TECHNOL MANAGE, V50, P55 DIMASI JA, 2007, MANAG DECIS EC, V28, P469, DOI 10.1002/mde.1360 LANE C, 2007, IND INNOV, V14, P5, DOI 10.1080/13662710601130574 Pisano GP, 2006, HARVARD BUS REV, V84, P114 Dhanaraj C, 2006, ACAD MANAGE REV, V31, P659 Lee YH, 2006, PROD PLAN CONTROL, V17, P518, DOI 10.1080/09537280600804976 Arthurs JD, 2006, J BUS VENTURING, V21, P195, DOI 10.1016/j.jbusvent.2005.04.004 ROTHMAN H, 2006, J COMMERCIAL BIOTECH, V12, P86, DOI 10.1057/palgrave.jcb.3040154 Laroia G, 2005, RES TECHNOL MANAGE, V48, P42 Hoang H, 2005, ACAD MANAGE J, V48, P332 Danzon PM, 2005, J HEALTH ECON, V24, P317, DOI 10.1016/j.jhealeco.2004.09.006 GASSMANN O, 2005, CREATIVITY INNOVATIO, V14, P233, DOI 10.1111/j.1467-8691.2005.00344.x OSTERWALDER A, 2005, COMMUNICATIONS ASS I, V15, P3 Scarbrough H, 2004, ORGAN STUD, V25, P1579, DOI 10.1177/0170840604048001 GASSMANN O, 2004, LEADING PHARM INNOVA DiMasi JA, 2003, J HEALTH ECON, V22, P151, DOI 10.1016/S0167-6296(02)00126-1 BAMFIELD P, 2003, RES DEV MANAGEMENT C BIGRAS Y, 2002, CMA MANAGEMENT FISKEN J, 2002, J COMMERCIAL BIOTECH, V8, P191 Prencipe A, 2001, RES POLICY, V30, P1373, DOI 10.1016/S0048-7333(01)00157-3 Rothaermel FT, 2001, STRATEGIC MANAGE J, V22, P687, DOI 10.1002/smj.180 GOVINDARAJAN V, 2001, BUS HORIZONS, V44, P3, DOI 10.1016/S0007-6813(01)80041-0 SAWHNEY M, 2001, HARVARD BUS REV, P76 Weisenfeld U, 2001, R&D MANAGE, V31, P91, DOI 10.1111/1467-9310.00199 Baum JAC, 2000, STRATEGIC MANAGE J, V21, P267, DOI 10.1002/(SICI)1097-0266(200003)21:3<267::AID-SMJ89>3.0.CO;2-8 PAPADOPOULOS S, 2000, NATURE BIOTECHNOLO S, V18 TEECE DJ, 2000, MANAGING INTELLECTUA Powell WW, 1998, CALIF MANAGE REV, V40, P228 ORSENIGO L, 1998, J MANAGEMENT GOVERNA, V1, P147 RUGMAN A, 1997, EUROPEAN MANAGEMENT, V15, P403, DOI 10.1016/S0263-2373(97)00019-4 Liebeskind JP, 1996, ORGAN SCI, V7, P428, DOI 10.1287/orsc.7.4.428 Powell WW, 1996, ADMIN SCI QUART, V41, P116, DOI 10.2307/2393988 CHESBROUGH HW, 1996, HARVARD BUSINESS REV LORENZONI G, 1995, CALIF MANAGE REV, V37, P146 ARORA A, 1994, RES POLICY, V23, P523, DOI 10.1016/0048-7333(94)01003-X ARORA A, 1994, J ECON BEHAV ORGAN, V24, P91, DOI 10.1016/0167-2681(94)90055-8 SHAN WJ, 1994, STRATEGIC MANAGE J, V15, P387, DOI 10.1002/smj.4250150505 WASSERMAN S, 1994, ADV SOCIAL NETWORK A BRASS DJ, 1993, ACAD MANAGE J, V36, P441, DOI 10.2307/256588 DIMASI JA, 1991, J HEALTH ECON, V10, P107, DOI 10.1016/0167-6296(91)90001-4 PISANO GP, 1990, ADMIN SCI QUART, V35, P153, DOI 10.2307/2393554 PETTIGREW AM, 1990, ORGAN SCI, V1, P267, DOI 10.1287/orsc.1.3.267 POWELL WW, 1990, RES ORGAN BEHAV, V12, P295 EISENHARDT KM, 1989, ACAD MANAGE REV, V14, P532, DOI 10.2307/258557 PISANO GP, 1988, INT COLLABORATIVE VE, P183 TEECE DJ, 1986, RES POLICY, V15, P285, DOI 10.1016/0048-7333(86)90027-2 NR 53 TC 1 Z9 1 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0953-7287 J9 PROD PLAN CONTROL JI Prod. Plan. Control PY 2010 VL 21 IS 2 BP 218 EP 228 DI 10.1080/09537280903441971 PG 11 WC Engineering, Industrial; Engineering, Manufacturing; Operations Research & Management Science SC Engineering; Operations Research & Management Science GA 564ES UT WOS:000275196700008 ER PT J AU Durand, R Bruyaka, O Mangematin, V AF Durand, Rodolphe Bruyaka, Olga Mangematin, Vincent TI DO SCIENCE AND MONEY GO TOGETHER? THE CASE OF THE FRENCH BIOTECH INDUSTRY SO STRATEGIC MANAGEMENT JOURNAL LA English DT Article DE rent generation; rent appropriations; value drivers; biotech industry ID RESEARCH-AND-DEVELOPMENT; RESOURCE-BASED VIEW; COMPETITIVE ADVANTAGE; INTERORGANIZATIONAL COLLABORATION; INTERFIRM COOPERATION; PRODUCT DEVELOPMENT; FIRM PERFORMANCE; ALLIANCES; INNOVATION; KNOWLEDGE AB Developing technological applications, entering exploitation alliances, and choosing between research- or service-focused strategic orientations are decisions that high-tech firms must manage concurrently. This article explores systematically the contrasting effects of these strategic determinants on rent generation mid rent appropriation using the entire population of French biotech firms (1994-2002). Findings indicate that science and money do not unconditionally go together-the direct relationship between rent-accruing resources (e.g., patents or articles) and rent appropriation varies depending oil the type of resources and the strategic orientation. Moreover, the effects of strategic determinants differ for rent generation vs. rent appropriation: 1) technological application diversity undermines a firm's capacity to appropriate rents-in particular for research-oriented firms; 2) exploitation alliances favor rent generation but hinder rent appropriation; 3) service-oriented firms exhibit significantly better performance than research-oriented firms. Such evidence challenges the emergence in the biotechnology industry of a 'one-best' strategic trajectory. as represented by research-intensive start-ups funded by Private money engaged in publishing and patenting races. Copyright (C) 2008 John Wiley & Sons, Ltd. C1 [Durand, R] HEC Sch Management, Paris, France. [Bruyaka, O] Virginia Tech, Blacksburg, VA USA. [Mangematin, V] Grenoble Ecole Management, Grenoble, France. [Mangematin, V] GAEL INRA UPMF, Grenoble, France. RP Durand, R (reprint author), HEC Sch Management, 1 Rue Liberat, F-78351 Jouy En Josas, France EM durand@hec.fr CR Mc Namara P, 2007, RES POLICY, V36, P548, DOI 10.1016/j.respol.2007.02.012 Stuart TE, 2007, RES POLICY, V36, P477, DOI 10.1016/j.respol.2007.02.016 Sampson RC, 2007, ACAD MANAGE J, V50, P364 Morrow JL, 2007, STRATEGIC MANAGE J, V28, P271, DOI 10.1002/smj.579 Sirmon DG, 2007, ACAD MANAGE REV, V32, P273 Dhanaraj C, 2006, ACAD MANAGE REV, V31, P659 Lavie D, 2006, ACAD MANAGE REV, V31, P638 Rothaermel FT, 2006, J BUS VENTURING, V21, P429, DOI 10.1016/j.jbusvent.2005.02.006 VANBEUZEKOM B, 2006, OECD BIOTECHNOLOGY S Nesta L, 2005, J IND ECON, V53, P123, DOI 10.1111/j.0022-1821.2005.00248.x DEBERDT D, 2005, ACT P INPI PAR GREENE WH, 2005, ECONOMETRIC ANAL Powell WW, 2005, AM J SOCIOL, V110, P1132, DOI 10.1086/421508 Soh PH, 2004, ACAD MANAGE J, V47, P907 Alvarez SA, 2004, J BUS VENTURING, V19, P621, DOI 10.1016/j.jbusvent.2003.09.002 Tijssen RJW, 2004, RES POLICY, V33, P709, DOI 10.1016/j.respol.2003.11.002 Baum JAC, 2004, J BUS VENTURING, V19, P411, DOI 10.1016/S0883-9026(03)00038-7 O'Reilly CA, 2004, HARVARD BUS REV, V82, P74 Rothaermel FT, 2004, STRATEGIC MANAGE J, V25, P201, DOI 10.1002/smj.376 BAE J, 2004, ACAD MANAGE J, V47, P860 REISS T, 2004, SCI PUBL POLICY, V15, P344 Niosi J, 2003, RES POLICY, V32, P737, DOI 10.1016/S0048-7333(02)00083-5 Gittelman M, 2003, MANAGE SCI, V49, P366, DOI 10.1287/mnsc.49.4.366.14420 Mangematin V, 2003, RES POLICY, V32, P621, DOI 10.1016/S0048-7333(02)00045-8 Coff RW, 2003, STRATEGIC MANAGE J, V24, P183, DOI 10.1002/smj.270 Gulati R, 2003, STRATEGIC MANAGE J, V24, P127, DOI 10.1002/smj.287 Somaya D, 2003, STRATEGIC MANAGE J, V24, P17, DOI 10.1002/smj.281 ALLANSDOTTIR A, 2002, INNOVATION COMPETITI Zucker LG, 2002, MANAGE SCI, V48, P138, DOI 10.1287/mnsc.48.1.138.14274 Durand R, 2001, J BUS VENTURING, V16, P471, DOI 10.1016/S0883-9026(99)00061-0 Shane S, 2001, MANAGE SCI, V47, P1173, DOI 10.1287/mnsc.47.9.1173.9785 Rothaermel FT, 2001, STRATEGIC MANAGE J, V22, P687, DOI 10.1002/smj.180 Sarkar MB, 2001, STRATEGIC MANAGE J, V22, P701, DOI 10.1002/smj.179 Arundel A, 2001, RES POLICY, V30, P611, DOI 10.1016/S0048-7333(00)00100-1 Rosenkopf L, 2001, STRATEGIC MANAGE J, V22, P287, DOI 10.1002/smj.160 Alvarez SA, 2001, ACAD MANAGE EXEC, V15, P139 *ERNST YOUNG, 2001, LIF SCI FRANC 2001 C OWENSMITH J, 2001, J TECHNOLOGY TRANSFE, V26, P99, DOI 10.1023/A:1007892413701 Stuart TE, 2000, STRATEGIC MANAGE J, V21, P791, DOI 10.1002/1097-0266(200008)21:8<791::AID-SMJ121>3.0.CO;2-K Baum JAC, 2000, STRATEGIC MANAGE J, V21, P267, DOI 10.1002/(SICI)1097-0266(200003)21:3<267::AID-SMJ89>3.0.CO;2-8 Gulati R, 2000, STRATEGIC MANAGE J, V21, P203, DOI 10.1002/(SICI)1097-0266(200003)21:3<203::AID-SMJ102>3.0.CO;2-K AFUAH A, 2000, STRATEGIC MANAGEMENT, V21, P397, DOI 10.1002/(SICI)1097-0266(200003)21:3<397::AID-SMJ88>3.3.CO;2-T Almeida P, 1999, MANAGE SCI, V45, P905, DOI 10.1287/mnsc.45.7.905 Moran P, 1999, ACAD MANAGE REV, V24, P390, DOI 10.2307/259133 Stuart TE, 1999, ADMIN SCI QUART, V44, P315, DOI 10.2307/2666998 Coff RW, 1999, ORGAN SCI, V10, P119, DOI 10.1287/orsc.10.2.119 Meyer-Krahmer F, 1998, RES POLICY, V27, P835, DOI 10.1016/S0048-7333(98)00094-8 Lane PJ, 1998, STRATEGIC MANAGE J, V19, P461, DOI 10.1002/(SICI)1097-0266(199805)19:5<461::AID-SMJ953>3.0.CO;2-L Zucker LG, 1998, AM ECON REV, V88, P290 MORRISON S, 1998, BIOTECH 99 BRIDGING Teece DJ, 1997, STRATEGIC MANAGE J, V18, P509, DOI 10.1002/(SICI)1097-0266(199708)18:7<509::AID-SMJ882>3.0.CO;2-Z Levinthal DA, 1997, MANAGE SCI, V43, P934, DOI 10.1287/mnsc.43.7.934 Powell WW, 1996, ADMIN SCI QUART, V41, P116, DOI 10.2307/2393988 Deeds DL, 1996, J BUS VENTURING, V11, P41, DOI 10.1016/0883-9026(95)00087-9 WINTER SG, 1995, RESOURCE BASED EVOLU, P147 LERNER J, 1994, RAND J ECON, V25, P319, DOI 10.2307/2555833 SHAN WJ, 1994, STRATEGIC MANAGE J, V15, P387, DOI 10.1002/smj.4250150505 LEVINTHAL DA, 1993, STRATEGIC MANAGE J, V14, P95, DOI 10.1002/smj.4250141009 PETERAF MA, 1993, STRATEGIC MANAGE J, V14, P179, DOI 10.1002/smj.4250140303 BARNEY J, 1991, J MANAGE, V17, P99, DOI 10.1177/014920639101700108 HUNTER JE, 1990, METHODS METAANALYSIS FRANKLIN JJ, 1988, HDB QUANTITATIVE STU, P325 HEALEY P, 1986, RES POLICY, V15, P233, DOI 10.1016/0048-7333(86)90024-7 CARROLL GR, 1985, AM J SOCIOL, V90, P1262, DOI 10.1086/228210 WILLIAMSON OE, 1985, EC I CAPITALISM PENROSE ET, 1959, THEORY GROWTH FIRM NR 66 TC 5 Z9 5 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 0143-2095 J9 STRATEG MANAGE J JI Strateg. Manage. J. PD DEC PY 2008 VL 29 IS 12 BP 1281 EP 1299 DI 10.1002/smj.707 PG 19 WC Business; Management SC Business & Economics GA 378GU UT WOS:000261310000002 ER PT J AU Lignier, P Mangematin, S Morfin, F Rousset, JL Caps, V AF Lignier, Pascal Mangematin, Stephane Morfin, Franck Rousset, Jean-Luc Caps, Valerie TI Solvent and oxidant effects on the Au/TiO2-catalyzed aerobic epoxidation of stilbene RID C-7471-2009 RID B-7389-2011 SO CATALYSIS TODAY LA English DT Article DE gold; epoxidation; aerobic; oxygen; solvent; peroxide; radical ID ABSOLUTE RATE CONSTANTS; HYDROGEN-ATOM ABSTRACTION; HYDROCARBON OXIDATION; MOLECULAR-OXYGEN; PEROXY RADICALS; LIQUID-PHASE; CATALYSTS; COMPLEXES; ALKANES; ACETONITRILE AB Molecular oxygen can be used as the main oxidant to selectively epoxidize trans-stilbene over Au/TiO2 catalysts, in a free-radical process. However, the nature of the radical initiator has a critical influence on the reaction selectivity. tert-Butylhydroperoxide (TBHP, catalytic amount) leads to high yields of epoxide; on the other hand, hydrogen peroxide and di-tert-butylperoxide merely cause degradation of trans-stilbene. The choice of the solvent is also critical. Amongst the selected solvents. only alkyl-substituted cyclohexanes lead to high yields of epoxide, despite the poor dispersion of the catalytic powder. Other solvents. including the more polar ones and cyclohexane, are significantly less efficient, both in terms of total activity and epoxide production. The latter does not go beyond the yield expected from the potential stoichiometric reaction between TBHP and trans-stilbene (5%). On the basis of these results, an aerobic epoxidation mechanism is proposed in which molecular oxygen is activated by a substituted cyclohexyl radical produced by abstraction of a tertiary hydrogen atom from the solvent molecule by a tert-butylperoxy radical. (C) 2008 Elsevier B.V. All rights reserved. C1 [Lignier, P; Mangematin, S; Morfin, F; Rousset, JL; Caps, V] Univ Lyon, CNRS, IRCELYON, F-69626 Villeurbanne, France. RP Caps, V (reprint author), Univ Lyon, CNRS, IRCELYON, 2 Ave Albert Einstein, F-69626 Villeurbanne, France EM valerie.caps@ircelyon.univ-lyon1.fr FU French Ministry for Education and Research FX The authors are grateful to the French Ministry for Education and Research for P.L.'s Ph.D. grant and to Professor M. Haruta for advice on the regeneration of the reference catalyst. CR Li AR, 2007, J CHEM ENG DATA, V52, P2339, DOI 10.1021/je700330c Dimitratos N, 2007, CATAL TODAY, V122, P317, DOI 10.1016/j.cattod.2007.01.002 Lignier P, 2007, CATAL TODAY, V122, P284, DOI 10.1016/j.cattod.2007.02.006 Lignier P, 2007, CHEM COMMUN, P186, DOI 10.1039/b610546g Hughes MD, 2005, NATURE, V437, P1132, DOI 10.1038/nature04190 Buda F, 2005, COMBUST FLAME, V142, P170, DOI 10.1016/j.combustflame.2005.03.005 Horstmann S, 2004, J CHEM THERMODYN, V36, P1015, DOI 10.1016/j.jct.2004.07.014 Wentzel BB, 2004, J ORG CHEM, V69, P3453, DOI 10.1021/jo030345a Ahmad S, 2004, COORDIN CHEM REV, V248, P231, DOI 10.1016/j.cct.2003.10.015 Kunkely H, 2003, INORG CHEM COMMUN, V6, P553, DOI 10.1016/S1387-7003(03)00040-6 REICHARDT C, 2003, SOLVENTS SOLVENT EFF, P471 LOROSCH J, 2001, PROCESS ENV CHEM CYA Wentzel BB, 1998, J CHEM SOC DALTON, P2241, DOI 10.1039/a801175c Ashcroft SJ, 1997, J CHEM ENG DATA, V42, P1244, DOI 10.1021/je9701588 Ingold KU, 1997, CATAL LETT, V48, P21, DOI 10.1023/A:1019074920329 Mizuno N, 1996, J MOL CATAL A-CHEM, V114, P15, DOI 10.1016/S1381-1169(96)00301-9 Minisci F, 1996, SYNLETT, P119 LASSILA KR, 1994, TETRAHEDRON LETT, V35, P8077, DOI 10.1016/0040-4039(94)88247-9 KANEDA K, 1992, TETRAHEDRON LETT, V33, P6827, DOI 10.1016/S0040-4039(00)61786-0 SWAY MI, 1991, J CHEM SOC FARADAY T, V87, P2157, DOI 10.1039/ft9918702157 PARKER AJ, 1984 CHENIER JHB, 1978, CAN J CHEM, V56, P3047, DOI 10.1139/v78-498 PAUL H, 1978, J AM CHEM SOC, V100, P4520, DOI 10.1021/ja00482a033 HOWARD JA, 1972, ADV FREE RADICAL CHE, V4, P49 INGOLD KU, 1969, ACCOUNTS CHEM RES, V2, P1, DOI 10.1021/ar50013a001 HOWARD JA, 1968, CAN J CHEM, V46, P2655, DOI 10.1139/v68-437 HOWARD JA, 1967, CAN J CHEM, V45, P793, DOI 10.1139/v67-132 MIDDLETON BS, 1967, CAN J CHEM, V45, P191, DOI 10.1139/v67-038 KERR JA, 1966, CHEM REV, V66, P465, DOI 10.1021/cr60243a001 PYLE WR, 1931, PHYS REV, V38, P1057, DOI 10.1103/PhysRev.38.1057 NR 30 TC 15 Z9 15 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-5861 J9 CATAL TODAY JI Catal. Today PD OCT 15 PY 2008 VL 138 IS 1-2 BP 50 EP 54 DI 10.1016/j.cattod.2008.04.026 PG 5 WC Chemistry, Applied; Chemistry, Physical; Engineering, Chemical SC Chemistry; Engineering GA 353KS UT WOS:000259566400010 ER PT J AU Mangematin, V Baden-Fuller, C AF Mangematin, Vincent Baden-Fuller, Charles TI Global contests in the production of business knowledge: Regional centres and individual business schools RID A-8163-2008 SO LONG RANGE PLANNING LA English DT Article ID TECHNOLOGICAL DISCONTINUITIES; MANAGEMENT; JOURNALS; SCIENCE; TENURE; DETERMINANTS; PUBLICATION; SELECTION; ACADEMICS; ARTICLES AB Drawing on institutional theory, the global production of business research is analysed by examining the system of written outputs using one of the largest databases of journal papers ever assembled, covering over 65,000 articles produced by more than 54,000 authors from over 8,000 different institutions across the period 1992-2005. We acknowledge the pioneering role of US business schools in establishing the modern institutional system of undertaking and disseminating research that involves the intertwining of university business schools and scientific journals. While Wharton and Harvard are still the leading universities globally, their crowns are slipping, together with the position of the US generally. We observe the greatest challenges to the existing order as coming from European and Asian institutions that have either copied, or been inspired to innovate by adapting, the US system. London Business School, Erasmus, INSEAD and Tilburg are threatening to topple leading US universities in the undertaking of research, and other European and Asian institutions are close behind. It is argued that international businesses can now go to non-US institutions to find leaders in thought. (C) 2007 Elsevier Ltd. All rights reserved. C1 [Mangematin, V] UMR GAEL INRA Univ Pierre Mendes, F-38040 Grenoble 9, France. [Baden-Fuller, C] City Univ London, Cass Business Sch, London EC1Y 8TZ, England. RP Mangematin, V (reprint author), UMR GAEL INRA Univ Pierre Mendes, F-38040 Grenoble 9, France EM vincent@grenoble.inra.fr c.baden-fuller@city.ac.uk CR Tushman ML, 2007, ACAD MANAG LEARN EDU, V6, P345 Antunes D, 2007, LONG RANGE PLANN, V40, P382, DOI 10.1016/j.lrp.2007.04.003 Ilgen DR, 2007, ACAD MANAGE J, V50, P507 Judge TA, 2007, ACAD MANAGE J, V50, P491 Leung K, 2007, ACAD MANAGE J, V50, P510 *AACSB, 2007, IMP RES TASK FORC RE DJELIC ML, 2007, PKU BUSINESS REV, V32, P122 MONASTERKY R, 2007, J MARKETING, V71, P171 Harmon MM, 2006, ACAD MANAG LEARN EDU, V5, P234 VANDEVEN A, 2006, ACAD MANAGE REV, V31, P516 Podsakoff PM, 2005, STRATEGIC MANAGE J, V26, P473, DOI 10.1002/smj.454 Starbuck WH, 2005, ORGAN SCI, V16, P180, DOI 10.1287/orsc.1040.0107 Durand R, 2005, ORGAN STUD, V26, P165, DOI 10.1177/0170840605049465 GREENE WH, 2005, ECONOMETRIC ANAL VERHAEGEN P, 2005, J MANAGEMENT DEV, V24, P807, DOI 10.1108/02621710510621312 Baden-Fuller C, 2001, LONG RANGE PLANN, V34, P741, DOI 10.1016/S0024-6301(01)00088-7 Siow A, 1998, J LAW ECON ORGAN, V14, P152 Elsbach KD, 1996, ADMIN SCI QUART, V41, P442, DOI 10.2307/2393938 Park SH, 1996, STRATEGIC MANAGE J, V17, P109, DOI 10.1002/(SICI)1097-0266(199602)17:2<109::AID-SMJ796>3.0.CO;2-P Baldi S, 1995, SOCIOL QUART, V36, P777, DOI 10.1111/j.1533-8525.1995.tb00464.x LAREDO P, 1992, SCI TECHNOLOGY POLIC ANDERSON P, 1990, ADMIN SCI QUART, V35, P604, DOI 10.2307/2393511 DJELIC ML, 1990, BUS HIST, V49, P483 CARMICHAEL HL, 1988, J POLIT ECON, V96, P453, DOI 10.1086/261547 BARLEY SR, 1988, ADMIN SCI QUART, V33, P24, DOI 10.2307/2392854 LATOUR B, 1987, SCI ACTION TUSHMAN ML, 1986, ADMIN SCI QUART, V31, P439, DOI 10.2307/2392832 DIAMOND AM, 1986, J HUM RESOUR, V21, P200 DOSI G, 1982, RES POLICY, V11, P147, DOI 10.1016/0048-7333(82)90016-6 COLE J, 1971, AM SOCIOL, V6, P23 CRANE D, 1967, AM SOCIOL, V2, P195 MERTON R, 1965, SHOULDERS GIANTS SHA KUHN TS, 1962, STRUCTURE SCI REVOLU GORDON AR, 1959, HIGHER ED BUSINESS NR 34 TC 9 Z9 9 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0024-6301 J9 LONG RANGE PLANN JI Long Range Plan. PD FEB PY 2008 VL 41 IS 1 BP 117 EP 139 DI 10.1016/j.lrp.2007.11.005 PG 23 WC Business; Management; Planning & Development SC Business & Economics; Public Administration GA 284VR UT WOS:000254735400009 ER PT S AU Sabatier, V Mangematin, V Rousselle, T AF Sabatier, Valerie Mangematin, Vincent Rousselle, Tristan BE CamarinhaMatos, LM Picard, W TI Going virtual in the European biopharmaceutical industry: Conductors and oxpeckers make it SO PERVASIVE COLLABORATIVE NETWORKS SE International Federation for Information Processing LA English DT Proceedings Paper CT 9th Working Conference on Virtual Enterprises CY SEP 08-10, 2008 CL Poznan, POLAND SP IFIP TC 5 WG 5 5 ID INNOVATION AB In the sector of biopharmaceuticals, the dominant business model remains the one of big pharmas: the vertical integration. However we currently observe in the European biotechnology industry the emergence of new business models. This article studies in particular the cases of an orchestra firm and a repurposing firm, both virtual all along the value chain of drugs. It shows that being virtual is possible in the European biopharmaceutical industry. Small virtual firms are able to play the role of hub firms in networks. These organizations, despite their small size and limited funding, manage to build networks with academics and industrials, long-run partnerships, mid, icing on the cake: the drug development cost should be much lower than big pharmas'. C1 [Sabatier, V; Mangematin, V] Univ Grenoble 2, GAEL, UMR 1215, F-38000 Grenoble, France. EM valeriesabatier@proteinexpert.com vincent@grenoble.inra.f tristanrousselle@proteinexpert.com CR Chong CR, 2007, NATURE, V448, P645, DOI 10.1038/448645a Hopkins MM, 2007, RES POLICY, V36, P566, DOI 10.1016/j.respol.2007.02.013 Siggelkow N, 2007, ACAD MANAGE J, V50, P20 DIMASI JA, 2007, MANAG DECIS EC, V28, P469, DOI 10.1002/mde.1360 Mesquita LF, 2007, ACAD MANAGE REV, V32, P72 Dhanaraj C, 2006, ACAD MANAGE REV, V31, P659 DiMasi JA, 2003, J HEALTH ECON, V22, P151, DOI 10.1016/S0167-6296(02)00126-1 BAMFIELD P, 2003, STRUCTURAL COMPONENT GOVINDARAJAN V, 2001, BUS HORIZONS, P3 SAWHNEY M, 2001, HARVARD BUS REV, P76 Weisenfeld U, 2001, R&D MANAGE, V31, P91, DOI 10.1111/1467-9310.00199 Cooper WW, 2000, J ORG COMP ELECT COM, V10, P189, DOI 10.1207/S15327744JOCE1003_03 MAGRETTA J, 1998, HARVARD BUSINESS MAR, P73 RUGMAN A, 1997, EUROPEAN MANAGEMENT, V15, P403, DOI 10.1016/S0263-2373(97)00019-4 CHESBROUGH HW, 1996, HARVARD BUSINESS REV LORENZONI G, 1995, CALIF MANAGE REV, V37, P146 EISENHARDT KM, 1989, ACAD MANAGE REV, V14, P532, DOI 10.2307/258557 PROVAN KG, 1983, ACAD MANAGE REV, V8, P79, DOI 10.2307/257170 NR 18 TC 0 Z9 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES SN 1571-5736 BN 978-0-387-84836-5 J9 INT FED INFO PROC PY 2008 VL 283 BP 93 EP 104 PG 12 WC Computer Science, Information Systems; Computer Science, Theory & Methods SC Computer Science GA BID44 UT WOS:000258620100010 ER PT J AU Bozeman, B Laredo, P Mangematin, V AF Bozeman, Barry Laredo, Philippe Mangematin, Vincent TI Understanding the emergence and deployment of "nano" S&T RID A-8163-2008 SO RESEARCH POLICY LA English DT Article DE nanotechnology; industrial dynamics; science policy; institution ID TECHNOLOGICAL DISCONTINUITIES; INNOVATION; INDUSTRY; FIRM; PERFORMANCE; EXPERIENCE; KNOWLEDGE; NETWORKS; SCIENCE; BIRTH AB As an introduction to the special issue on "emerging nanotechnologies", this paper puts in perspective contemporary debates and challenges about nanotechnology. It presents an overview of diverse analyses and expectations about this presumably revolutionary set of technological, scientific and industrial developments. Three main lines of argument can then be delineated: first of all, the degree of cumulativeness of science and technologies and the respective roles of newcomers and incumbents in the industrial dynamics; second the knowledge dynamics in nanotechnologies, especially the linkages by science and technology and third the role of institutions (network, geographic agglomeration and job market). It finally discusses methodologies to delineate the field of nanotechnologies and to collect data. (C) 2007 Published by Elsevier B.V. C1 Univ Georgia, Dept Publ Adm & Policy, Athens, GA 30602 USA. Univ Paris Est ENPC, F-77455 Marne La Vallee 2, France. Manchester Business Sch, F-77455 Marne La Vallee 2, France. UPMF, GAEL, INRA, F-38040 Grenoble, France. Grenoble Ecol Management, F-38040 Grenoble, France. RP Bozeman, B (reprint author), Univ Georgia, Dept Publ Adm & Policy, 201 Baldwin Hall, Athens, GA 30602 USA EM bbozeman@uga.edu philippe.laredo@enpc.fr vincent@grenoble.inra.fr CR Avenel E, 2007, RES POLICY, V36, P864, DOI 10.1016/j.respol.2007.02.002 Bonaccorsi A, 2007, RES POLICY, V36, P813, DOI 10.1016/j.respol.2007.02.009 Guan JC, 2007, RES POLICY, V36, P880, DOI 10.1016/j.respol.2007.02.004 Mogoutov A, 2007, RES POLICY, V36, P893, DOI 10.1016/j.respol.2007.02.005 Robinson DKR, 2007, RES POLICY, V36, P871, DOI 10.1016/j.respol.2007.02.003 Rothaermel FT, 2007, RES POLICY, V36, P832, DOI 10.1016/j.respol.2007.02.008 Stephan P, 2007, RES POLICY, V36, P887, DOI 10.1016/j.respol.2007.02.006 Zucker LG, 2007, RES POLICY, V36, P850, DOI 10.1016/j.respol.2007.02.007 Kostoff RN, 2006, J NANOPART RES, V8, P301, DOI 10.1007/s11051-005-9035-8 Jong S, 2006, IND CORP CHANGE, V15, P251, DOI 10.1093/icc/dtj014 Kostoff RN, 2006, J NANOPART RES, V8, P193, DOI 10.1007/s11051-005-9034-9 Mustar P, 2006, RES POLICY, V35, P289, DOI 10.1016/j.respol.2005.11.001 BLIND K, 2006, EC INNOVATION NEW TE, V15, P157, DOI 10.1080/10438590500143970 PORTER A, 2006, ATL C SCI TECHN POL Dietz JS, 2005, RES POLICY, V34, P349, DOI 10.1016/j.respol.2005.01.008 Rothaermel FT, 2005, RES POLICY, V34, P305, DOI 10.1016/j.respol.2004.11.006 Boschma RA, 2005, REG STUD, V39, P61, DOI 10.1080/0034340052000320887 BONACCORSI A, 2005, SEARCH REGIMES IND D Bozeman B, 2004, RES POLICY, V33, P565, DOI 10.1016/S0048-7333(04)00012-5 Corolleur CDF, 2004, RES POLICY, V33, P631, DOI 10.1016/S0048-7333(04)00017-4 PORRO B, 2004, NANOTECHNOLOGY SMALL Hill CWL, 2003, ACAD MANAGE REV, V28, P257 DARBY M, 2003, 9825 NBER NOYONS CM, 2003, MAPPING EXCELLENCE S Powell WW, 2002, REG STUD, V36, P291, DOI 10.1080/00343400220122089 Hite JM, 2001, STRATEGIC MANAGE J, V22, P275, DOI 10.1002/smj.156 PICKSTONE JV, 2001, WAYS KNOWING NEW HIS Almeida P, 1999, MANAGE SCI, V45, P905, DOI 10.1287/mnsc.45.7.905 Zucker LG, 1998, AM ECON REV, V88, P290 AFUAH A, 1997, IND CORP CHANGE, V6, P183 UTTERBACK JM, 1993, RES POLICY, V22, P1, DOI 10.1016/0048-7333(93)90030-L ANDERSON P, 1990, ADMIN SCI QUART, V35, P604, DOI 10.2307/2393511 TUSHMAN ML, 1986, ADMIN SCI QUART, V31, P439, DOI 10.2307/2392832 DOSI G, 1982, RES POLICY, V11, P147, DOI 10.1016/0048-7333(82)90016-6 ABERNATHY WJ, 1978, TECHNOL REV, V80, P41 KUHN TS, 1962, STRUCTURE SCI REVOLU NR 36 TC 13 Z9 13 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0048-7333 J9 RES POLICY JI Res. Policy PD JUL PY 2007 VL 36 IS 6 BP 807 EP 812 DI 10.1016/j.respol.2007.02.010 PG 6 WC Management; Planning & Development SC Business & Economics; Public Administration GA 191PE UT WOS:000248142600001 ER EF